Recombinant gastric lipase - Meristem

Drug Profile

Recombinant gastric lipase - Meristem

Alternative Names: Merispase®; Recombinant gastric lipase

Latest Information Update: 03 Feb 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Meristem Therapeutics
  • Class Carboxylic ester hydrolases
  • Mechanism of Action Lipase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic disorders

Highest Development Phases

  • Discontinued Pancreatic disorders

Most Recent Events

  • 25 Feb 2005 Profile reviewed with information presented at the 3rd Annual BioPartnering North America (BPN-2005)
  • 25 Feb 2005 Recombinant gastric lipase is available for licensing (
  • 21 Jun 2004 Phase-II clinical trials in Pancreatic disorders in Europe (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top